written by Sarah L. Minor

Imagine a cancer treatment that’s as unique as you are. Katia Khoury, M.D., assistant professor of medicine in the Division of Hematology and Oncology, recently published findings from a new “sequential therapy approach” to breast cancer investigations in Nature Medicine. The innovative trial design is at the forefront of personalized cancer care.

As part of the I-SPY2.2 trial, Khoury and colleagues studied the effects of treatment administered in three sequential blocks, they found that the drug Datopotamab-deruxtecan (Dato-DXd) was effective in producing an estimated pathological complete response (pCR) rate of 38.1% in the whole treatment strategy in different breast cancer subtypes, half of which were achieved after Dato-DXd alone.

In the hormone receptor-negative, HER2 negative, immune negative, DNA repair deficiency negative subtype, the pCR rate was 41% after completing full treatment, outperforming the control.

For more details on this trial, visit the Nature Magazine website to read the full article.